Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 09, 2023

BUY
$63.71 - $70.74 $318 - $353
5 Added 0.12%
4,155 $265,000
Q4 2022

Feb 09, 2023

SELL
$68.48 - $81.09 $821 - $973
-12 Reduced 0.29%
4,150 $298,000
Q3 2022

Oct 31, 2022

BUY
$0.13 - $76.84 $1 - $922
12 Added 0.29%
4,162 $295,000
Q2 2022

Aug 05, 2022

SELL
$72.62 - $79.98 $205,224 - $226,023
-2,826 Reduced 40.51%
4,150 $319,000
Q1 2022

May 13, 2022

BUY
$61.48 - $73.72 $77,341 - $92,739
1,258 Added 22.0%
6,976 $440,000
Q4 2021

Apr 08, 2022

BUY
$53.63 - $62.52 $302,634 - $352,800
5,643 Added 7524.0%
5,718 $356,000
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $295,876 - $344,922
-5,517 Reduced 98.66%
75 $356,000
Q2 2021

Aug 12, 2021

SELL
$61.91 - $67.42 $85,683 - $93,309
-1,384 Reduced 19.84%
5,592 $373,000
Q1 2021

May 06, 2021

SELL
$59.34 - $66.74 $3,441 - $3,870
-58 Reduced 0.82%
6,976 $440,000
Q3 2020

Nov 03, 2020

BUY
$57.43 - $63.64 $402,239 - $445,734
7,004 Added 23346.67%
7,034 $424,000
Q2 2020

Aug 10, 2020

SELL
$54.82 - $64.09 $412,739 - $482,533
-7,529 Reduced 99.6%
30 $444,000
Q1 2020

Apr 28, 2020

BUY
$46.4 - $67.43 $5,382 - $7,821
116 Added 1.56%
7,559 $421,000
Q4 2019

Feb 04, 2020

BUY
$49.21 - $64.19 $25,835 - $33,699
525 Added 7.59%
7,443 $477,000
Q2 2019

Jul 25, 2019

SELL
$44.62 - $49.34 $10,128 - $11,200
-227 Reduced 3.18%
6,918 $314,000
Q1 2019

Apr 18, 2019

BUY
$45.12 - $53.8 $676 - $807
15 Added 0.21%
7,145 $340,000
Q2 2018

Jul 30, 2018

SELL
$50.53 - $62.98 $63,162 - $78,725
-1,250 Reduced 14.92%
7,130 $394,000
Q4 2017

Jan 16, 2018

BUY
$59.94 - $65.35 $87,632 - $95,541
1,462 Added 21.13%
8,380 $513,000
Q3 2017

Oct 18, 2017

BUY
$55.23 - $63.74 $382,081 - $440,953
6,918
6,918 $441,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Baltimore Washington Financial Advisors, Inc. Portfolio

Follow Baltimore Washington Financial Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baltimore Washington Financial Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Baltimore Washington Financial Advisors, Inc. with notifications on news.